- Malaysia
- /
- Healthcare Services
- /
- KLSE:FOCUSP
Focus Point Holdings Berhad Second Quarter 2025 Earnings: EPS: RM0.014 (vs RM0.014 in 2Q 2024)
Focus Point Holdings Berhad (KLSE:FOCUSP) Second Quarter 2025 Results
Key Financial Results
- Revenue: RM72.8m (up 3.1% from 2Q 2024).
- Net income: RM8.45m (flat on 2Q 2024).
- Profit margin: 12% (in line with 2Q 2024).
- EPS: RM0.014 (in line with 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Focus Point Holdings Berhad Earnings Insights
Looking ahead, revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Healthcare industry in Malaysia.
Performance of the Malaysian Healthcare industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with Focus Point Holdings Berhad.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KLSE:FOCUSP
Focus Point Holdings Berhad
An investment holding company, operates professional eye care centers in Malaysia.
Very undervalued with flawless balance sheet and pays a dividend.
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets
Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Investment Analysis (May 2026)
Recently Updated Narratives
3REN Berhad Is Powering the Semiconductor Ecosystem and Smart Manufacturing
Cheeding: The Hidden Beneficiary of Malaysia’s Power Grid Expansion
KRMN — Karman Space & Defense: Down 58% from Peak, Is the Market Mispricing a Hypergrowth Defense Compounder?
Popular Narratives

Investment Analysis (May 2026)

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Honeywell - The Demand-Side of the AI Infrastructure
Trending Discussion
It's wonderful. It has greatly helped me take informed decisions.
